Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2014

View Archived Issues

Alnylam and Genzyme expand collaboration for RNAi therapeutics

Idenix Pharmaceuticals reports data from phase II all-oral HCV combination regimen

GSK obtains option right to Santaris Pharma's LNA technology

Vaxart's H1N1 influenza vaccine shows promising protective immunity in phase Ib study

Cortice Biosciences begins enrollment in phase II trial of TPI-287 plus Avastin

Cancer Prevention Pharmaceuticals and Tillotts Pharma sign licensing agreement

Seattle Genetics and AbbVie expand antibody-drug conjugate collaboration

Probiodrug and VU University Medical Center to collaborate on Alzheimer's disease biomarker assays

Extended treatment phase of ZS-9 phase III trial in hyperkalemia meets endpoint

Achillion describes clinical development plan for oral HCV treatments

FDA clears BD Diagnostics' BD MAX MRSA XT Assay

GeoVax discloses preliminary topline results from phase I trial of vaccine to control HIV infections

Metabolic suppression-mediated discovery of novel antibacterial inhibitor compounds

Discovery and characterization of an orally potent anti-inflammatory kinase inhibitor

FDA grants QIDP designation to Carbavance

EMA committee recommends suspending use of Protelos/Osseor

Prosensa regains rights to drisapersen from GSK

First patient dosed in phase II trial of BMN-111 in children with achondroplasia

First subjects dosed in phase Il study of NKTR-171

FDA committee recommends approval of Northera NDA for treatment of symptomatic nOH

Complement factor B inhibitors described in recent Novartis patent

Boehringer Ingelheim describes K(Ca) 3.1 channel blockers

Roche reports development of tankyrase inhibitors

U.S. researchers divulge novel bacterial RNA polymerase inhibitors

MAP Pharmaceuticals patent discloses D2/5-HT1D receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.